Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric nirmatrelvir/ritonavir for nonhospitalized symptomatic COVID-19 at risk of severe disease
2023-509773-23-00Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of Nirmatrelvir and ritonavir in coronavirus disease 2019 (COVID-19), sponsored by Pfizer. Primary endpoints: Plasma nirmatrelvir pharmacokinetic parameters and Safety and tolerability. Started Apr 2022; status: completed.
02
Drugs
Nirmatrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2023-509773-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509773-23-00.